Entrada Therapeutics (TRDA) Reports Q1 Net Loss of $21.7M

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. ANET
7. SWKS
8. XYZ
9. CVS
10. SPY

Go back to Entrada Therapeutics (TRDA) Reports Q1 Net Loss of $21.7M

Entrada Therapeutics Reports First Quarter 2022 Financial Results

May 12, 2022 7:00 AM EDT

Second clinical candidate, ENTR-701, announced for the potential treatment of myotonic dystrophy type 1

On track to submit Investigational New Drug application to the U.S. Food and Drug Administration for ENTR-601-44 targeting Duchenne muscular dystrophy in Q4 2022

$263.9 million in cash, cash equivalents and marketable securities as of March 31, 2022 to advance pipeline of Endosomal Escape Vehicle (EEV) therapeutic candidates

BOSTON, May 12, 2022 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing... More